Bristol Myers Squibb (BMY) Notes Payables (2009 - 2016)
Bristol Myers Squibb (BMY) reported Notes Payables of $155.0 million for Q2 2016, down 79.47% year-over-year from $755.0 million in Q3 2015, and up 46.23% on a QoQ basis from $106.0 million in Q1 2016.
Bristol Myers Squibb (BMY) has 8 years of Notes Payables data on file, last reported at $155.0 million in Q2 2016.
- Quarterly Notes Payables fell 79.47% year-over-year to $155.0 million in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $155.0 million (down 79.47% YoY) and the FY2015 annual result came in at $139.0 million, down 76.44% from the prior year.
- Notes Payables improved to $155.0 million in Q2 2016 per BMY's latest filing, from $106.0 million in the prior quarter.
- Across five years, Notes Payables topped out at $1.4 billion in Q1 2013 and bottomed at $106.0 million in Q1 2016.
- The 5-year median for Notes Payables is $383.0 million (2014), against an average of $494.3 million.
- The widest annual swing landed in 2013, when Notes Payables soared 846.21%; it then sank 79.52% in 2014.
- Tracing BMY's Notes Payables over 5 years: stood at $826.0 million in 2012, then tumbled by 56.54% to $359.0 million in 2013, then soared by 64.35% to $590.0 million in 2014, then plunged by 76.44% to $139.0 million in 2015, then gained by 11.51% to $155.0 million in 2016.
- Per Business Quant, the three latest BMY Notes Payables figures stand at $155.0 million (Q2 2016), $106.0 million (Q1 2016), and $139.0 million (Q4 2015).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 155.00 Mn |
| Mar 31, 2016 | 106.00 Mn |
| Dec 31, 2015 | 139.00 Mn |
| Sep 30, 2015 | 642.00 Mn |
| Jun 30, 2015 | 755.00 Mn |
| Mar 31, 2015 | 330.00 Mn |
| Dec 31, 2014 | 590.00 Mn |
| Sep 30, 2014 | 401.00 Mn |
| Jun 30, 2014 | 365.00 Mn |
| Mar 31, 2014 | 281.00 Mn |
| Dec 31, 2013 | 359.00 Mn |
| Sep 30, 2013 | 680.00 Mn |
| Jun 30, 2013 | 764.00 Mn |
| Mar 31, 2013 | 1.37 Bn |
| Dec 31, 2012 | 826.00 Mn |
| Sep 30, 2012 | 751.00 Mn |
| Jun 30, 2012 | 236.00 Mn |
| Mar 31, 2012 | 145.00 Mn |
| Dec 31, 2011 | 115.00 Mn |
| Sep 30, 2011 | 182.00 Mn |
| Jun 30, 2011 | 187.00 Mn |
| Mar 31, 2011 | 135.00 Mn |
| Dec 31, 2010 | 117.00 Mn |
| Dec 31, 2009 | 231.00 Mn |
| Sep 30, 2009 | 286.00 Mn |
| Jun 30, 2009 | 124.00 Mn |